# A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232

> **NCT07538466** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Addpharma Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** AD-123
- **DRUG:** AD-1231 and AD-1232

## Key facts

- **NCT ID:** NCT07538466
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07538466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07538466, "A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07538466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*